All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Qualit-E-SpeakPharma-Insert

X

Find FDA Investigational New Drug (IND) Submissions for Musculoskeletal

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

Country

News Type

Company

Product Type

Deal Size

refresh

Product Type

Companies

Celavet

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Celavet Inc. Plans Submission of Equine Tendinitis Study to FDA’s Center for Veterinary Medicine

Contact the Supplier

Lead Product(s): OK100 stem cell

Therapeutic Area: Musculoskeletal

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2020

Details:

Celavet is submitting the study protocol to the CVM for Investigational New Animal Drug (INAD) status.

Cadent Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Cadent Therapeutics Announces FDA Acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)

Contact the Supplier

Lead Product(s): Cad-1883

Therapeutic Area: Musculoskeletal

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

The Phase 2 trial is a multicenter, randomized, placebo-controlled study that will evaluate the safety and efficacy of CAD-1883. Efficacy outcome measures.